HIV post-exposure prophylaxis (PEP) after occupational and non-occupational exposure

International Congress Series

Volumn 1279, Issue , 2005, Pages 105-108

  Prins, J M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

HIV; Occupational exposure; Prophylaxis

Indexed keywords

EID: 33646577492     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2005.01.010     Document Type: Article

References (17)

1. Cardo D.M., et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. centers for disease control and prevention needlestick surveillance group. N. Engl. J. Med. 337 (1997) 1485-1490
2. Wade N.A., et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N. Engl. J. Med. 339 (1998) 1409-1414
3. The Petra study team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet 359 (2002) 1178-1186
4. Bottiger D., et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS 11 (1997) 157-162
5. Otten R.A., et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J. Virol. 74 (2000) 9771-9775
6. Tsai C.C., et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J. Virol. 72 (1998) 4265-4273
7. Quirino T., et al. HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients. Antivir. Ther. 5 (2000) 195-197
8. Benn P.D., et al. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet 357 (2001) 687-688
9. Kahn J.O., et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP study. J. Infect. Dis. 183 (2001) 707-714
10. Puro V. Post-exposure prophylaxis for HIV infection. Italian registry of post-exposure prophylaxis. Lancet 355 (2000) 1556-1557
11. Bleker O.P., et al. Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing. [Dutch Institute for Health Care Improvement revised guideline, 'Sexually transmitted diseases and neonatal herpes']. Ned. Tijdschr. Geneeskd. 147 (2003) 695-699
12. Gray R.H., et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357 (2001) 1149-1153
13. Sutcliffe S., et al. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. J. Acquir. Immune Defic. Syndr. 31 (2002) 90-97
14. Wald A., and Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J. Infect. Dis. 185 (2002) 45-52
15. Cohen M.S., et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1, AIDSCAP Malawi research group. Lancet 349 (1997) 1868-1873
16. Dyer J.R., et al. Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi. J. Infect. Dis. 177 (1998) 224-227
17. Lowe S.H., et al. Is the male genital tract really a sanctuary site for HIV? Arguments that it is not. AIDS 18 (2004) 1353-1362